Open: 5.94 Close: 5.83 Change: -0.11

Today's Summary

addex announced today publication of preclinical data supporting potential of mglu7 negative allosteric modulators to transform anxiety and fear-related disorder treatment. mGlu7 targeting metabotropic glutamate receptor 7 (mGlu7) with negative mRNAs (NAM) could be transformative in the treatment of anxiety and anxiety-related disorders, such as post-traumatic stress disorder.Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. addex partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies.